Issue Date: November 25, 2013
Cancer Protein Meets Its Match
Scientists have devoted lots of time and money trying to find inhibitors of human Ras proteins. About 30% of cancers depend on mutated versions of Ras for growth and survival, making Ras mutants appealing cancer drug targets.
The fruits of these efforts have been molecules that bind Ras mutants only weakly or inhibit them indirectly by preventing the proteins from localizing in cell membranes, where Ras signaling occurs. But neither type of inhibitor has proven . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society